The debate between yourself and Cafa is terrific, so thanks to both of you.
Question: can we boil it down this way ....
If we take an Overall Survival as a proxy for PFS (which I know will not be announced until the conference, and will not be finalised until the FOXFIRE trial reports) then:
1. If you have inoperable mCRC in the liver only, the use of SIRT as a first-line therapy will lengthen OS (by at least by 3 months). Crudely, 100% of these patients die of liver cancer and if the trial sample was representative, then 60% of all mCRC patients fall in this category.
2. If you have inoperable mCRC in the liver and elsewhere AND you were going to die of liver cancer, then its a reasonable assumption that the use of SIRT as a first-line therapy would lengthen OS. Its not proved yet, but its possible that OS may be lengthened by the same amount of time as group 1 (even though at the time of death, tumors in the other parts of the body would be significantly larger). Further, if the trial sample was representative, then 75% of these patients die of liver cancer (since 90% of all mCRC patients die of liver cancer) - ie, this group represents 30% of people with mCRC.
3. If you have inoperable mCRC in the liver and elsewhere AND you were going to die of a cancer other than liver cancer, then the use of SIRT as a first-line therapy would have no impact on OS. If the trial sample was representative, then this group represents 10% of people with mCRC.
Based on my basic understanding of statistics, this 3rd group would have been enough for the trial to fail its primary end-point. Nevertheless, if the assumptions / inferences about the 2nd group are correct, then I would still expect doctors to prescribe SIRT as a first line of treatment for anyone with mCRC in the liver (regardless of whether its in the liver only).
Thoughts appreciated.
- Forums
- ASX - By Stock
- SRX
- Destined to fail
Destined to fail, page-39
-
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $56.24M |
Open | High | Low | Value | Volume |
13.0¢ | 13.5¢ | 13.0¢ | $109.3K | 836.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 365703 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 812922 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 365703 | 0.130 |
6 | 379702 | 0.125 |
2 | 288500 | 0.120 |
1 | 135000 | 0.115 |
3 | 23177 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 308222 | 2 |
0.140 | 773121 | 13 |
0.145 | 280000 | 3 |
0.150 | 109631 | 6 |
0.160 | 70000 | 1 |
Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online